Rabbitts T H, Forster A, Larson R, Nathan P
MRC Laboratory of Molecular Biology, Cambridge, UK.
Nat Genet. 1993 Jun;4(2):175-80. doi: 10.1038/ng0693-175.
The search for tumour-specific markers is one of the chief goals in cancer biology. We show that the translocation t(12;16)(q13:p11) in malignant myxoid liposarcoma can be a fusion of the CHOP dominant negative transcription factor gene with a novel gene, FUS, which can result in fusion of the FUS glycine-rich protein with the whole CHOP coding region. The data support the concept that protein fusion may commonly occur in solid tumours resulting in tumour-specific markers of potential clinical importance. The data also indicate the importance of transcription disruption in the pathogenesis of solid tumours.
寻找肿瘤特异性标志物是癌症生物学的主要目标之一。我们发现,恶性黏液样脂肪肉瘤中的易位t(12;16)(q13:p11)可能是CHOP显性负转录因子基因与一个新基因FUS的融合,这可能导致FUS富含甘氨酸的蛋白与整个CHOP编码区融合。这些数据支持了蛋白质融合可能在实体瘤中普遍发生并产生具有潜在临床重要性的肿瘤特异性标志物这一概念。数据还表明转录破坏在实体瘤发病机制中的重要性。